FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Wagner Kristie Ann		 2. Date of Event Requiring Statement (MM/DD/YYYY)
2/24/2022 

 3. Issuer Name and Ticker or Trading Symbol

Entasis Therapeutics Holdings Inc. [ETTX]
(Last)        (First)        (Middle)

C/O ENTASIS THERAPEUTICS HOLDINGS INC.,, 35 GATEHOUSE DRIVE		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
VP, Principal Fin & Acct Off /
(Street)

WALTHAM, MA 02451      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 70500 (1)D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (Right to Buy)  (2)6/6/2031 Common Stock 73400 $2.40 D  
Explanation of Responses:
(1) Represents a restricted stock unit award granted on January 18, 2022. The award vests over four years with twenty-five percent (25%) of the award vesting on each anniversary of the date of grant, subject to the reporting person's continued employment with the Company through each such date.
(2) Twenty-five percent (25%) of the shares subject to the option shall vest on June 7, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person's continued employment with the Company through each such date.

Remarks:
See Exhibit 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Wagner Kristie Ann
C/O ENTASIS THERAPEUTICS HOLDINGS INC.,
35 GATEHOUSE DRIVE
WALTHAM, MA 02451

VP, Principal Fin & Acct Off
Signatures
/s/ Elizabeth M. Keiley as Attorney-in-Fact for Kristie Wagner2/24/2022
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Entasis Therapeutics (NASDAQ:ETTX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Entasis Therapeutics.
Entasis Therapeutics (NASDAQ:ETTX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Entasis Therapeutics.